RxSight, Inc. RXST

Healthcare SIC 3851 - Ophthalmic Goods NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Ophthalmic Goods Manufacturing derived Nasdaq

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight® Light Adjustable Lens system ("RxSight system") is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens®(LAL®/LAL+®, collectively the "LAL"), RxSight Light Delivery Device ("LDD™") and related accessories. The LAL is a premium intraocular lens ("IOL") made from the proprietary silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet ("UV") light patterns generated by the LDD.

Last close 5.02 2026-10-23
Market cap $208.8M 2026-06-30 share count
52-week range 4.40 - 13.22

Valuation FY2025 figures against the last close

P/S1.6x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.95

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue $134.5M$139.9M$89.1M$49.0M$22.6M$14.7M—
Cost of revenue $31.5M$41.0M$35.3M$27.7M$18.1M$13.0M—
Gross profit $103.0M$98.9M$53.8M$21.3M$4.5M$1.7M—
R&D $38.5M$34.4M$29.1M$26.0M$24.5M$21.9M—
SG&A $112.7M$101.4M$74.8M$58.7M$32.8M$15.2M—
Total operating expenses $151.2M$135.8M$103.8M$84.6M$57.3M$37.1M—
Operating income -$48.2M-$36.9M-$50.1M-$63.3M-$52.8M-$35.4M—
Interest expense $19.0K$21.0K$3.3M$4.9M$3.7M$510.0K—
Pre-tax income -$38.9M-$27.4M-$48.6M-$66.7M-$48.7M$27.6M—
Income tax $66.0K$50.0K$20.0K$9.0K$8.0K$57.0K—
Net income -$39-$28-$49-$67-$48.7M$27.6M—
EPS, basic -0.95-0.71-1.41-2.41-3.570.91—
EPS, diluted -0.95-0.71-1.41-2.41-3.570.15—
Shares, diluted (wtd. avg.) 40.9M38.9M34.5M27.7M13.6M5.5M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents $19.9M$16.7M$10.4M$12.6M$25.2M$14.5M$8.8M
Short-term investments $208.2M$220.5M$117.5M$94.0M$135.0M$55.0M—
Receivables $23.4M$30.1M$20.3M$11.0M$4.9M$2.9M—
Inventory $31.6M$22.0M$17.4M$14.8M$8.0M$8.3M—
Total current assets $287.5M$293.8M$168.4M$134.6M$176.3M$81.5M—
Property, plant and equipment $13.1M$12.4M$10.8M$10.1M$11.2M$13.3M—
Total assets $311.8M$318.6M$182.6M$150.2M$192.7M$100.7M—
Accounts payable $5.3M$4.5M$3.9M$2.6M$1.7M$1.1M—
Total current liabilities $26.3M$25.9M$20.9M$17.2M$11.1M$11.6M—
Long-term debt ——$0$40.2M$39.8M$24.4M—
Total liabilities $36.1M$37.3M$22.2M$60.3M$54.5M$44.9M—
Retained earnings -$661.0M-$622.1M-$594.6M-$546.0M-$479.3M-$430.6M—
Total equity $275.7M$281.2M$160.4M$89.9M$138.2M-$430.6M-$419.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating cash flow -$15.5M-$16.9M-$41.6M-$58.9M-$44.7M-$35.2M—
Depreciation and amortisation $3.3M$3.6M$4.1M$3.9M$4.0M$3.9M—
Stock-based compensation $31.6M$24.6M$15.7M$11.4M$7.6M$4.2M—
Capital expenditure $3.8M$5.4M$4.8M$2.4M$1.9M$2.5M—
Investing cash flow $16.9M-$99.3M-$22.1M$40.0M-$81.9M$15.6M—
Financing cash flow $1.9M$123.3M$61.5M$6.3M$137.3M$25.2M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-187240.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -50M 0 50M 100M 150M Revenue, FY2020: 14.7M Gross profit, FY2020: 1.7M Net income, FY2020: 27.6M Revenue, FY2021: 22.6M Gross profit, FY2021: 4.5M Net income, FY2021: -48.7M Revenue, FY2022: 49M Gross profit, FY2022: 21.3M Net income, FY2022: -66.8 Revenue, FY2023: 89.1M Gross profit, FY2023: 53.8M Net income, FY2023: -48.6 Revenue, FY2024: 139.9M Gross profit, FY2024: 98.9M Net income, FY2024: -27.5 Revenue, FY2025: 134.5M Gross profit, FY2025: 103M Net income, FY2025: -38.9 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $14.7M $22.6M $49.0M $89.1M $139.9M $134.5M
Gross profit — $1.7M $4.5M $21.3M $53.8M $98.9M $103.0M
Net income — $27.6M -$48.7M -$67 -$49 -$28 -$39

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3851

TickerCompanyMarket capP/ERevenue growth
COO COOPER COMPANIES, INC. $11.94B 32.7x 5.1%
BLCO Bausch & Lomb Corp $6.24B — 6.5%
WRBY Warby Parker Inc. $3.21B 2,591.0x 13.0%
EYE National Vision Holdings, Inc. $1.48B 50.5x 9.0%
STAA STAAR SURGICAL CO $1.13B — -23.7%
LUCY Innovative Eyewear Inc $7.5M — 62.6%
ALC ALCON INC — — 4.9%